Erez Kalir brings a wealth of experience as an investor, entrepreneur, and thought leader with a deep focus on life sciences and technology. He currently serves as the Managing Member of Martial Eagle Fund and as a Venture Partner at FJ Labs, renowned for its leadership in early-stage venture investments. He also authors the influential […]
Team Role: Board
Fouad Namouni, MD
Fouad Namouni, MD brings more than 20 years of oncology and cancer immunotherapy drug development expertise, as well as clinical experience as a pediatric oncologist. Since September 2020, he has served as President of Research & Development at Blueprint Medicines, providing key leadership as the company built a fully integrated global business and overseeing all […]
Josh Resnick, MD
Josh Resnick, MD is a Managing Director at RA Capital Management. Josh’s primary responsibility at RA Capital is to lead early-stage private investments and oversee the creation of new companies developing drugs, medical devices, diagnostics, and research tools. He has more than 15 years of experience in investing, company formation, and company leadership across all […]
Matthew R. Patterson
Matt Patterson is a biotechnology executive with more than 30 years of experience in the research, development, and commercialization of innovative therapeutics. In 2012 Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the Company’s inception until its acquisition by Astellas Pharma Inc. in January 2020. Mr. Patterson was also Chairman of the […]
Bill Lundberg, MD
Bill Lundberg, MD is a medical oncologist with more than two decades of experience managing and leading biotechnology research and development. Bill is President and CEO at Merus, a clinical-stage oncology company developing innovative, full-length multispecific antibodies. Prior to joining Merus, he served as Chief Scientific Officer at CRISPR Therapeutics, where he was responsible for […]
David Lubner
David Lubner is a senior finance executive with more than 25 years of experience in the life sciences industry. David served as Executive Vice President and Chief Financial Officer of Ra Pharma until May 2020 following its acquisition by UCB. Prior to Ra Pharma, he was Senior Vice President and Chief Financial Officer of Tetraphase […]
Daniella Beckman
Daniella Beckman has deep financial and operational experience across the biotechnology industry, having worked with both private and publicly traded companies throughout her career. At Tango Therapeutics, Daniella oversees finance, investor relations, and business development. Prior to joining Tango, she was a consultant to early-stage biotechnology companies, leading financial activities and building companies’ financial infrastructures. […]
Robert Ang, MBBS, MBA
Robert Ang, MBBS, MBA, is President and CEO at Vor Bio since 2019. Prior to Vor Bio, Robert gained operational experience focused on strategy and business development through roles at Neon Therapeutics (now BioNTech), Bavarian Nordic, and Cadence Pharmaceuticals (now Mallinckrodt). Robert also has biotech venture capital experience at Frazier Healthcare Ventures, where he invested […]